ZFIN ID: ZDB-FISH-150901-3111
Fish name: zc7Tg
Genotype: zc7Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by zc7Tg
Human Disease Conditions Citations
diabetic neuropathy high glucose Waldron et al., 2017
GENE EXPRESSION
Gene expression in zc7Tg
RNA expression
Expressed Gene Structure Conditions Figures
adcy1a standard conditions Fig. S1 from Xu et al., 2010
adcy1b standard conditions Fig. S1 from Xu et al., 2010
adcy8 standard conditions Fig. 2 from Xu et al., 2010
cdh10a control Fig. 7 from Zecca et al., 2015
chrna2a control Fig. 1 from Menelaou et al., 2014
crestin control Fig. 5 from Zecca et al., 2015
chemical treatment by environment: leflunomide Fig. 5 from Zecca et al., 2015
neurod1 control Fig. 7 from Zecca et al., 2015
pax2a standard conditions Fig. 3 with image from Pittman et al., 2008
prkcaa standard conditions Fig. 7 from Palanca et al., 2013
robo2 control Fig. 6,  Fig. 7 from Zecca et al., 2015
robo3 control Fig. 6,  Fig. 7 from Zecca et al., 2015
slit1a control Fig. 6 from Zecca et al., 2015
slit1b control Fig. 6 from Zecca et al., 2015
snai1b control Fig. 7 from Zecca et al., 2015
PHENOTYPE
Phenotype in zc7Tg
Phenotype Conditions Figures
caudal fin sensory neuron morphology, abnormal high glucose Fig. 2 from Waldron et al., 2017
cranial ganglion fused with cranial ganglion, abnormal chemical treatment by environment: leflunomide Fig. 5 from Zecca et al., 2015
cranial nerve II decreased thickness, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 7 with image from Seritrakul et al., 2017
cranial nerve VIII axon extension arrested, abnormal light ablation: anterior lateral line ganglion, light ablation: statoacoustic (VIII) ganglion Fig. 4 from Zecca et al., 2015
cranial neural crest cell absent, abnormal chemical treatment by environment: leflunomide Fig. 5 from Zecca et al., 2015
dorsal root ganglion decreased amount, abnormal chemical treatment: azumolene sodium Fig. 4 with image from Klatt Shaw et al., 2018
dorsal root ganglion decreased amount, abnormal chemical treatment by environment: thapsigargin Fig. 4 with image from Klatt Shaw et al., 2018
dorsal root ganglion decreased amount, abnormal chemical treatment by environment: aldrithiol Fig. 4 with image from Klatt Shaw et al., 2018
dorsal root ganglion decreased amount, abnormal chemical treatment by environment: N-acetyl-L-cysteine Fig. 4 with image from Klatt Shaw et al., 2018
dorsal root ganglion decreased amount, abnormal chemical treatment by environment: azumolene sodium Fig. 4 with image from Klatt Shaw et al., 2018
dorsal root ganglion decreased amount, abnormal chemical treatment by environment: Cyclopamine Fig. 4 with image from Klatt Shaw et al., 2018
dorsal root ganglion decreased amount, abnormal chemical treatment by environment: ryanodine Fig. 4 with image from Klatt Shaw et al., 2018
neural crest cell crestin expression absent, abnormal chemical treatment by environment: leflunomide Fig. 5 from Zecca et al., 2015
retina layer formation decreased occurrence, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 7 with image from Seritrakul et al., 2017
retinal ganglion cell decreased amount, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 7 with image from Seritrakul et al., 2017
sensory neuron apoptotic process increased process quality, abnormal chemical treatment: ethanol Fig. 5 with image from Joya et al., 2014
sensory neuron axon decreased amount, abnormal high glucose Fig. 2 from Waldron et al., 2017
sensory neuron axon decreased branchiness, abnormal high glucose Fig. 2 from Waldron et al., 2017
sensory neuron axon decreased diameter, abnormal high glucose Fig. 2 from Waldron et al., 2017
sensory neuron axon decreased length, abnormal high glucose Fig. 2 from Waldron et al., 2017
sensory neuron axon degeneration, abnormal high glucose Fig. 2 from Waldron et al., 2017
spinal cord has fewer parts of type sensory neuron, abnormal chemical treatment: ethanol Fig. 4 with image from Joya et al., 2014
statoacoustic (VIII) ganglion GFP expression decreased amount, abnormal control Figure 4 with image from Kantarci et al., 2020
statoacoustic (VIII) ganglion has extra parts of type neuron, abnormal chemical treatment by environment: lactate Figure 5 from Kantarci et al., 2020
statoacoustic (VIII) ganglion has fewer parts of type neuron, abnormal chemical treatment by environment: 2-deoxy-D-glucose Figure 5 from Kantarci et al., 2020
statoacoustic (VIII) ganglion has fewer parts of type neuron, abnormal chemical treatment by environment: pharmaceutical Figure 5 from Kantarci et al., 2020
statoacoustic (VIII) ganglion has fewer parts of type neuron, abnormal chemical treatment by environment: enzyme inhibitor Figure 5 from Kantarci et al., 2020
statoacoustic (VIII) ganglion has fewer parts of type neuron, abnormal chemical treatment by environment: dichloroacetate Figure 5 from Kantarci et al., 2020
statoacoustic (VIII) ganglion has fewer parts of type neuron, abnormal chemical treatment by environment: 3PO Figure 5 from Kantarci et al., 2020

CITATIONS  (36)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.